Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
October 6, 2017

Deals this week: Ixaltis, Arbutus Biopharma, Gesynta Pharma

French specialist pharmaceutical company Ixaltis has signed an agreement with Swiss biopharmaceutical company Xigen for worldwide rights to a compound being developed by the latter, targeting urogenital diseases.

French specialist pharmaceutical company Ixaltis has signed an agreement with Swiss biopharmaceutical company Xigen for worldwide rights to a compound being developed by the latter, targeting urogenital diseases.

The transaction enables the two companies to strengthen their urinary disorders product portfolio.

Canadian biopharmaceutical company Arbutus Biopharma plans to raise $116.4m through the private placement of convertible preferred shares.

Subscribed to by Roivant Sciences, the placement will enable Arbutus to accelerate the development of its HBV drug pipeline.

Research company Gesynta Pharma has acquired pharmaceuticals developer Orexo’s assets relating to the OX-MPI programme.

“Canadian biopharmaceutical company Arbutus Biopharma plans to raise $116.4m through the private placement of convertible preferred shares.”

The deal will help the company to advance its OX-MPI project into the clinical stage.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Both companies involved in the deal are based in Sweden.

KSQ Therapeutics has secured $76m in a venture financing round led by Flagship Pioneering.

The US-based biotechnology company plans to use the funds in order to advance its research and development activities.

Bermuda-based biopharmaceutical company SELLAS Life Sciences Group (SELLAS) has signed a clinical trial collaboration agreement with US-based pharmaceutical company Merck & Co’s subsidiary.

The two companies will carry out a combination clinical trial with galinpepimut-S and KEYTRUDA, under the agreement.

The trial will target multiple cancer types, including haematologic malignancies and solid tumours.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU